Diasome’s HDV-Insulin for T1D Finalizing Phase III Plans After Promising Data

T2Covered by 1 source · first reported by Fierce Biotech / Fierce Healthcare / MedCity / GEN at 18 Oct, 17:47 UTC

HDV is intended to address the difficulty of insulin, GLP-1, or other molecules traveling to the liver when injected subcutaneously, due to the large number of receptors in peripheral tissue such as fat cells and muscle cells. The post Diasome’s HDV-Insulin for T1D Finalizing Phase III Plans After…

science

Sources

• T2Diasome’s HDV-Insulin for T1D Finalizing Phase III Plans After Promising DataFierce Biotech / Fierce Healthcare / MedCity / GEN18 Oct, 17:47